Lung Cancer in 2021 and Beyond

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment. Topics include clinical decision-making, the extent emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.

December 3–4, 2021
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health

FACULTY CHAIR

Corey Langer, MD, FACP

University of Pennsylvania, PA, US

Faculty Members

Karen Reckamp, MD
Cedars-Sinai Medical Center, Los Angeles, CA, US

Edward Garon, MD, MS
University of California, Los Angeles, CA, US

Nasser Hanna, MD
Indiana University Simon Cancer Center, Indianapolis, IN, US

Antoinette Wozniak, MD, FACP, FASCO
UPMC Hillman Cancer Center, Pittsburgh, PA, US

Ignacio I. Wistuba, MD
MD Anderson Cancer Center, Houston, TX, US

Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, US

Natasha Leighl, MD, FASCO
University of Toronto, Ontario, Canada

David Spigel, MD
Sarah Cannon Research Institute, Nashville, TN, US

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

The report was based on the following topics

  • Prognostic and Predictive Biomarkers in NSCLC – Clinical vs Research Relevance (excluding EGFR/ALK)
  • New Directions for EGFR-Mutant NSCLC
  • Emergence of Immunotherapy and Bispecifics in SCLC
  • Therapeutic Landscape for Fusion-Positive NSCLC (ALK, ROS1, NTRK, RET)
  • Inhibiting Oncogenic Mutations: Overcoming Mutant KRAS, HER2, MET, and BRAF
  • New Directions for Second-Line Therapy
  • Perioperative Immunotherapy in Early NSCLC
  • Immunotherapy in Unresectable Stage III NSCLC
  • First-Line Immunotherapy in Metastatic NSCLC – Single Agent or Combination?
  • Biomarkers for Immunotherapy – Making Sense of the Chaos
  • EGFR (Less Common Mutations, Including Exon 20 Insertions)
  • Promising New Targets/Agents in Lung Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.